{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:06:41Z","timestamp":1784754401320,"version":"3.55.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20260204076"],"award-info":[{"award-number":["20260204076"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bioorg.2026.109546","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T06:51:15Z","timestamp":1769323875000},"page":"109546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?"],"prefix":"10.1016","volume":"172","author":[{"given":"Ya-Lan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhe","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Zhi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Kun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109546_bb0005","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1016\/S0960-9822(98)70032-6","article-title":"DNA repair: PARP-another guardian angel?","volume":"8","author":"Jeggo","year":"1998","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0010","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1093\/nar\/gkp229","article-title":"Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites","volume":"37","author":"Altmeyer","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0006-291X(63)90024-X","article-title":"Nicotinamide mononucleotil33 activation of a new dna-dfzendent polyaiienylic acid synthesizing nuclear \u2019enzyme","volume":"11","author":"Chambon","year":"1963","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0020","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1128\/MMBR.00040-05","article-title":"Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?","volume":"70","author":"Hassa","year":"2006","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.bioorg.2026.109546_bb0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nsmb.2335","article-title":"The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks","volume":"19","author":"Ali","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0030","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Hannah Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109546_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0050","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0055","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0065","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0070","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberga","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109546_bb0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0080","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast Cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bioorg.2026.109546_bb0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0105","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian Cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","article-title":"Reversion mutations with clinical use of PARP Inhibitors: many genes, many versions","volume":"7","author":"Domchek","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.molcel.2009.06.037","article-title":"A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency","volume":"35","author":"Cao","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0130","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M113.457440","article-title":"RIF1 counteracts BRCA1-mediated end resection during DNA repair","volume":"288","author":"Feng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0135","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","article-title":"A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice","volume":"49","author":"Escribano-Diaz","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0140","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0145","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100158","article-title":"SHLD2\/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice","volume":"37","author":"Findlay","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109546_bb0150","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1038\/s41467-018-06407-7","article-title":"An OB-fold complex controls the repair pathways for DNA double-strand breaks","volume":"9","author":"Gao","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0155","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-018-0362-1","article-title":"53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ","volume":"560","author":"Ghezraoui","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0160","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA repair network analysis reveals Shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0170","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899543","article-title":"FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells","volume":"37","author":"Tomida","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.bioorg.2026.109546_bb0175","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi Anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Katharina Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0185","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0190","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1038\/ncomms12425","article-title":"Synthetic viability by BRCA2 and PARP1\/ARTD1 deficiencies","volume":"7","author":"Ding","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0195","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0200","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","article-title":"Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells","volume":"20","author":"Dev","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0205","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast Cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0215","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0220","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0225","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.molcel.2021.04.028","article-title":"Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease","volume":"81","author":"Prokhorova","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0230","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Junko Murai","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109546_bb0235","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung Cancer","volume":"23","author":"Benjamin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0240","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/cb500135f","article-title":"An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states","volume":"9","author":"Echalier","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0245","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/ncb1109-1275","article-title":"Cyclin-dependent kinases: a family portrait","volume":"11","author":"Malumbres","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0255","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","article-title":"Transcription-associated cyclin-dependent kinases as targets and biomarkers for Cancer therapy","volume":"10","author":"Chou","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109546_bb0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0265","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-022-30264-0","article-title":"Inhibition of the CDK2 and cyclin a complex leads to autophagic degradation of CDK2 in cancer cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.109546_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108229","article-title":"Targeting CDK7 in oncology: the avenue forward","volume":"240","author":"Li","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109546_bb0280","doi-asserted-by":"crossref","first-page":"22095","DOI":"10.1021\/acs.jmedchem.5c02127","article-title":"Beyond inhibition: recent advances of heterobifunctional molecules targeting CDK9","volume":"68","author":"Yin","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jare.2025.01.017","article-title":"CDK8 mediated inflammatory microenvironment aggravates osteoarthritis progression","volume":"77","author":"Lin","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11033-025-10253-4","article-title":"CDK5: insights into its roles in diseases","volume":"52","author":"Wang","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bioorg.2026.109546_bb0295","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1038\/s41467-024-51229-5","article-title":"CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts","volume":"15","author":"Curti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0300","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrm2105","article-title":"Multiple levels of cyclin specificity in cell-cycle control","volume":"8","author":"Bloom","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0305","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.devcel.2010.02.013","article-title":"Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis","volume":"18","author":"Gavet","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0310","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1083\/jcb.147.2.295","article-title":"Human cyclin a is required for mitosis until mid prophase","volume":"147","author":"Furuno","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0315","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1535-7163.MCT-21-0604","article-title":"Olaparib-induced senescence is bypassed through G2-M checkpoint override in Olaparib-resistant prostate Cancer","volume":"21","author":"Lombard","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109546_bb0320","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ijo.2013.2240","article-title":"The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition","volume":"44","author":"Xia1","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0325","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109546_bb0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2022.11.006","article-title":"Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1\/BRCA1 pathway","volume":"168","author":"Yanaihara","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0335","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/1078-0432.CCR-16-0620","article-title":"Selective targeting of cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition","volume":"23","author":"George Au-Yeung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0340","article-title":"Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2","volume":"65","author":"Ryosuke Hayami","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0345","first-page":"111","article-title":"Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition, NPJ","volume":"7","author":"Aziz","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.109546_bb0350","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12964-025-02521-4","article-title":"Fadraciclib, a CDK2\/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression","volume":"23","author":"Kim","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.109546_bb0355","series-title":"CDK4\/6 Inhibitors Promote PARP1 degradation and Act Synergistically with PARP Inhibitors in Non-small Cell Lung cancer","author":"Roggero","year":"2024"},{"key":"10.1016\/j.bioorg.2026.109546_bb0360","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.redox.2017.12.017","article-title":"Downregulation of PARP1 transcription by CDK4\/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair","volume":"15","author":"Tempka","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102231","article-title":"CDK4\/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer","volume":"52","author":"Roggero","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0370","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00210-022-02375-4","article-title":"Novel combination treatment of CDK 4\/6 inhibitors with PARP inhibitors in triple negative breast cancer cells","volume":"396","author":"Guney Eskiler","year":"2023","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12282-021-01282-5","article-title":"Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors","volume":"29","author":"Suzuki","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bioorg.2026.109546_bb0380","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0385","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00894-025-06393-w","article-title":"Fused pyrido[3,4-D]pyrimidine moiety with phthalazinone ring accelerate dual inhibition of PARP1 and CDK4 in triple-negative breast cancer: a hybrid design with computational investigation through molecular modeling and quantum mechanics","volume":"31","author":"Sivakumar","year":"2025","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.bioorg.2026.109546_bb0390","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40164-023-00462-7","article-title":"Upregulated PARP1 confers breast cancer resistance to CDK4\/6 inhibitors via YB-1 phosphorylation","volume":"12","author":"Quan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0395","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/s41467-023-42736-y","article-title":"Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4\/6 inhibitors in treatment-refractory ER+ breast cancer","volume":"14","author":"Saatci","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0400","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-24-0903","article-title":"Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4\/6 inhibitors in prostate cancer","volume":"24","author":"Brandariz","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.109546_bb0405","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12964-024-01577-y","article-title":"CDK7 in breast cancer: mechanisms of action and therapeutic potential","volume":"22","author":"Gong","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2026.109546_bb0410","article-title":"PARP1 upregulation in recurrent Oral Cancer and treatment resistance","volume":"9","author":"Wang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0415","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jcb.26293","article-title":"CDK9: a key player in cancer and other diseases","volume":"119","author":"Franco","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0420","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1096\/fj.201801789RR","article-title":"Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer","volume":"33","author":"Wang","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2026.109546_bb0425","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","article-title":"Cyclin-dependent kinase (CDK) 9 and 4\/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach","volume":"28","author":"Lee","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.109546_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216820","article-title":"CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple negative breast cancer","volume":"589","author":"Orhan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.109546_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117367","article-title":"Design, synthesis and biological evaluation of dual CDK9\/PARP inhibitors for the treatment of cancer","volume":"287","author":"Huang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0440","first-page":"1211","article-title":"Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex","volume":"3","author":"Chu","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bioorg.2026.109546_bb0445","first-page":"eadu0847","article-title":"Acute BRCAness induction and AR pathway blockage through CDK12\/7\/9 degradation enhances PARP inhibitor sensitivity in prostate cancer, science","volume":"11","author":"Fu Gui","year":"2025","journal-title":"Advances"},{"key":"10.1016\/j.bioorg.2026.109546_bb0450","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2016.09.003","article-title":"Role and therapeutic potential of CDK12 in human cancers","volume":"50","author":"Chila","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2026.109546_bb0455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-017-0033-x","article-title":"The emerging roles of CDK12 in tumorigenesis","volume":"12","author":"Paculova","year":"2017","journal-title":"Cell Div"},{"key":"10.1016\/j.bioorg.2026.109546_bb0460","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.1038\/srep21455","article-title":"Cdk12 is a gene-selective RNA polymerase II kinase that regulates a subset of the transcriptome, including Nrf2 target genes","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109546_bb0465","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jclinpath-2018-205356","article-title":"CDK12: an emerging therapeutic target for cancer","volume":"71","author":"Lui","year":"2018","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bioorg.2026.109546_bb0470","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0475","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109546_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115648","article-title":"Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109546_bb0490","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses De novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast Cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2026.109546_bb0495","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast Cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109546_bb0500","article-title":"Synthetic lethal targeting of cyclin dependent kinase-12-Deficient prostate cancer with PARP inhibitors","volume":"30","author":"Jonathan Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0505","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.trecan.2016.09.001","article-title":"The emerging role of Cdk5 in Cancer","volume":"2","author":"Pozo","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109546_bb0510","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.apsb.2024.12.019","article-title":"CDK5-triggered G6PD phosphorylation at threonine 91 facilitating redox homeostasis reveals a vulnerability in breast cancer","volume":"15","author":"Bei","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109546_bb0515","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00018-011-0811-6","article-title":"The impact of cyclin-dependent kinase 5 depletion on poly(ADP-ribose) polymerase activity and responses to radiation","volume":"69","author":"Bolin","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2026.109546_bb0520","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1093\/nar\/gkw615","article-title":"Human CDK18 promotes replication stress signaling and genome stability","volume":"44","author":"Barone","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.109546_bb0525","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41467-019-10993-5","article-title":"Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma","volume":"10","author":"Ning","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109546_bb0530","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","article-title":"Extending benefit beyond BRCA-mutant cancers","volume":"25","author":"Pilie","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:56:20Z","timestamp":1784753780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":106,"alternative-id":["S0045206826000829"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109546","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it feasible for CDKs inhibitors to herald a new era in tackling the low sensitivity and drug resistance associated with PARP inhibitors?","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109546"}}